This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19 CAR-T in the treatment of refractory autoimmune diseases.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-01.
Status change: Not Yet Recruiting → Recruiting2026-04-21